inotrem
Inotrem is a biotechnology company specialized in immunotherapy for acute inflammatory syndromes, such as septic shock.
inotrem has raised €58M across 2 funding rounds from 3 investors, most recently a round in Dec 2020. Based in Paris, France; founded 2013; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€58M
€58,000,000
Funding rounds
2
Investors
3
distinct backers
Active since
2019-10
latest 2020-12
Funding by year
EUR raised per yearinotrem — funding by year — interactive chart.
Data table
| inotrem — funding by year | |
|---|---|
| 2019 | €39M |
| 2020 | €19M |
Signals
High confidenceRaise-next likelihood5
base rate 30% for Other
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Down/flat last round
- ▼ Low backer re-investment
Exit likelihood9
base rate 11% (2+ rounds)
- ▲ €30M+ raised
- ▼ No recent equity round (debt-only or quiet)
Timing: dormant vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2020-12-02 | Other | €19M | Fountain Healthcare Partners | View deal → |
| 2019-10-01 | Series B | €39M | Invus,Morningside Ventures | View deal → |
Related news
Similar companies
same sector or country- Mistral AI€6.5BFrance · AI
- Automotive Cells Company (ACC)€4.4BFrance · Transportation
- Philips€2.6BNetherlands · Healthtech
- Verkor€2.4BFrance · Energy
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
Global coverage: FundingData